Peter Behner
Known title: DirectorCIK: 0001851420
Associated companies
Transaction History
| INKT | ▲ Buy | Grant | 1,485 | $16K | 9/1/2026 | View on chart |
| INKT | ▲ Buy | Grant | 1,313 | $16K | 6/1/2026 | View on chart |
| INKT | ▲ Buy | Grant | 1,491 | $16K | 3/2/2026 | View on chart |
| INKT | ▲ Buy | Grant | 1,466 | $16K | 12/1/2025 | View on chart |
| INKT | ▲ Buy | Grant | 1,173 | $16K | 9/2/2025 | View on chart |
| INKT | ▲ Buy | Grant | 2,267 | $16K | 6/2/2025 | View on chart |
| INKT | ▲ Buy | Grant | 1,849 | $16K | 3/3/2025 | View on chart |
| INKT | ▲ Buy | Grant | 20,987 | $15K | 12/1/2024 | View on chart |
| INKT | ▲ Buy | Grant | 18,753 | $15K | 9/3/2024 | View on chart |
| INKT | ▲ Buy | Grant | 15,454 | $15K | 6/3/2024 | View on chart |
| INKT | ▲ Buy | Grant | 16,185 | $15K | 3/1/2024 | View on chart |
| INKT | ▲ Buy | Grant | 14,784 | $15K | 12/1/2023 | View on chart |
| INKT | ▲ Buy | Grant | 10,531 | $15K | 9/1/2023 | View on chart |
| INKT | ▲ Buy | Grant | 8,736 | $15K | 6/1/2023 | View on chart |
| INKT | ▲ Buy | Grant | 7,357 | $15K | 3/1/2023 | View on chart |
| INKT | ▲ Buy | Grant | 5,891 | $15K | 12/1/2022 | View on chart |
| INKT | ▲ Buy | Grant | 11,737 | $31K | 9/15/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
MiNK Therapeutics Chosen for ARPA‑H Cell Therapy Initiative
MiNK Therapeutics was selected by ARPA‑H for a funded initiative that aims to develop room‑temperature cell therapies. The partnership gives the company access to research resources and potential collaboration with other biotech firms. This could accelerate the progress of MiNK’s cell‑based products and increase investor interest in the company’s pipeline.
MiNK Therapeutics Chosen for ARPA‑H Cell Therapy Initiative. MiNK Therapeutics was selected by ARPA‑H for a funded initiative that aims to develop room‑temperature cell therapies. The partnership gives the company access to research resources and potential collaboration with other biotech firms. This could accelerate the progress of MiNK’s cell‑based products and increase investor interest in the company’s pipeline.